Novartis highlights affirmative Phase II psoriasis data; Meeker named Genzyme CEO ... FierceBiotech Novartis says a slate of mid-stage studies of AIN457 (secukinumab) proved promising in treating symptoms of moderate to severe plaque psoriasis . Story > David Meeker, who heads Genzyme's rare disease division, has been named CEO of the Boston biotech. ... and more » Link To Article
No comments:
Post a Comment